Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

675

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Datopotamab Deruxtecan
DRUG: Rilvegostomig
DRUG: Pembrolizumab

Sponsor

AstraZeneca

Collaborators

[object Object]